Her2 overexpression and amplification are more associated with gallbladder cholangiocarcinoma (9–14%) and extrahepatic cholangiocarcinoma (4–8%) than with ICC (1%) [16]. Here, ERBB2 is linked to intrahepatic cholangiocarcinoma.